All In Biotech

Drug Trial Radar · NCT02907567

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

A Randomized, Double-Blind, Placebo-Controlled, Phase I Study of the Safety & Pharmacokinetics of Two Doses of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Jul 26, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

19

Actual

Start

Sep 2016

Primary completion

Aug 24, 2017

Study completion Sep 2017

Sponsor

Lead sponsor
Cognition TherapeuticsIndustry
Sponsor type
Industry
First posted
Sep 20, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 50 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812, administered for 28 days. This trial may include up to 8 qualified investigator sites in Australia.

Conditions

  • Alzheimer's Disease

Interventions

  • CT1812Drug

    Active study drug

  • PlaceboDrug

    non-active study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence and review of Treatment Emergent Adverse EventsTime frame: Up to 30 days

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Dr. Phillip Morris

    Southport, Queensland, Australia

  • Austin Health

    Ivanhoe, Victoria, Australia

  • Epworth Hospital

    Melbourne, Victoria, Australia

  • The Royal Melbourne Hospital Hospital

    Parkville, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.